不同分子亚型年轻乳腺癌患者的复发模式:一项多样化当代队列研究
该研究回顾性分析了2008至2018年诊断的1431例40岁及以下I至III期乳腺癌患者,中位随访4.8年。结果显示16.1%的患者出现复发,其中74.8%为远处复发;复发率因分子亚型而异,HR+/HER2-且组织学3级和HR-/HER2+亚型复发率最高。保乳与全乳切除后单纯局部区域复发率数值相近。
要点
- 年轻乳腺癌患者中,HR+/HER2-且G3和HR-/HER2+亚型复发风险最高。
- 复发以远处转移为主,占全部复发的74.8%。
- 保乳与全乳切除后单纯局部区域复发率数值相近。
核心结论
- 在大型多样化年轻乳腺癌队列中,HR+/HER2-且G3或HR-/HER2+浸润性肿瘤的复发最频繁,且大多数为远处复发。
- 保乳与全乳切除后单纯局部区域复发在数值上相似,需进一步研究以识别复发预测因素。
研究设计与样本
- 回顾性队列研究,纳入2008至2018年诊断的40岁及以下I至III期乳腺癌患者1431例,中位随访4.8年(范围0.3至12.9年)。
- 收集临床病理特征、人口学资料和结局信息,采用卡方检验、Fisher精确检验及参数/非参数检验进行组间比较。
主要发现
- 随访期间共230例(16.1%)复发,其中74.8%为远处复发。
- 保乳患者单纯局部区域复发为17/463(3.7%),全乳切除患者为41/968(4.2%)(p < 0.001)。
- 各亚型复发率:HR+/HER2-且G1-2为14.0%,HR+/HER2-且G3为20.9%,HR+/HER2+为11.1%,HR-/HER2+为22.8%,HR-/HER2-为17.8%(p = 0.005)。
关键数值与推荐
- 队列中位年龄37岁(四分位距34至39岁),种族/族裔分布:白人41.8%、黑人7.8%、亚裔/太平洋岛民29.4%、西班牙裔19.6%、其他1.4%。
- 64.2%的患者初诊时为II/III期疾病。
临床怎么用
- 对于年轻乳腺癌患者,应关注HR+/HER2-且G3和HR-/HER2+亚型的高复发风险,加强随访和远处转移监测。
- 保乳与全乳切除后局部区域复发率数值相近,术式选择可综合其他因素个体化决策。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 中位随访时间4.8年相对较短,可能低估晚期复发事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Young breast cancer (YBC) patients are a unique subpopulation that are often underrepresented in randomized clinical trials. Furthermore, large national cancer databases lack detailed information on recurrence, a meaningful oncologic outcome for young patients. STUDY DESIGN: A retrospective review of YBC patients (age 40 years or younger) with stage I to III breast cancer diagnosed from 2008 to 2018 was performed. Information on clinicopathologic characteristics, demographics, and outcomes was obtained from the electronic health record and chart review. Chi-square and Fisher's exact tests were used for comparisons of categorical variables and parametric and nonparametric tests for continuous variables. RESULTS: The cohort included 1,431 women with a median follow-up of 4.8 years (range 0.3 to 12.9 years). The median age was 37 years (interquartile range 34 to 39). The study population included 598 (41.8%) White, 112 (7.8%) Black, 420 (29.4%) Asian/Pacific Islander, 281 (19.6%) Hispanic, and 20 (1.4%) "other" race/ethnicity patients. Tumor subtype was as follows: [1] hormone receptor (HR) + /human epidermal growth factor 2 (HER2 - ), grade (G) 1 to 2 = 541 (37.8%); [2] HR + /HER2 - , G3 = 268 (18.7%); [3] HR + /HER2 + = 262 (18.3%); [4] HR - /HER2 + = 101 (7.1%); [5] HR - /HER2 - = 259 (18.1%). The majority (64.2%) presented with stage II/III disease. There were 230 (16.1%) recurrences during follow-up; 74.8% were distant. Locoregional-only recurrence was seen in 17 of 463 (3.7%) patients who underwent breast conservation vs 41 of 968 (4.2%) patients undergoing mastectomy (p < 0.001). Recurrence varied by tumor subtype: [1] HR + /HER2 - , G1 to 2 (14.0%); [2] HR + /HER2 - , G3 (20.9%); [3] HR + /HER2 + (11.1%); [4] HR - /HER2 + (22.8%); [5] HR - /HER2 - (17.8%) (p = 0.005). CONCLUSIONS: In this large, diverse YBC cohort, recurrences were most frequent among HR + /HER2 - , G3, or HR - /HER2 + invasive tumors; most were distant. There were numerically similar locoregional-only recurrences after breast conservation vs mastectomy. Additional research is needed to identify predictors of recurrence.
引用
- Vuong B, Darbinian J, Savitz A, et al. Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. J Am Coll Surg. 2023. PMID: 37052317. doi:10.1097/XCS.0000000000000714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。